The U.S. Court of Appeals for the Federal Circuit on Sept. 3 upheld a lower court decision that maintains Bristol Myers Squibb and Pfizer’s U.S. exclusivity for their blockbuster heart drug Eliquis until 2028. The ruling is still subject to appeal, however. Eliquis is one of the top-selling drugs in the U.S., and currently holds covered or better status for 98% of all insured lives under the pharmacy benefit. 82.3% of all covered lives have unrestricted preferred access to Eliquis.

SOURCE: MMIT Analytics, as of 9/8/21